5.33
0.16 (3.09%)
0.16 (3.09%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Protalix BioTherapeutics Inc | PLX | AMEX | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.16 | 3.09% | 5.33 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 5.26 | 5.13 | 5.26 | 5.26 | 5.17 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,717 | 332,960 | $ 5.20 | $ 1,731,072 | 225,206 | 2.45 - 7.02 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 20:00:00 | 3,039 | $ 5.26 | USD |
Protalix BioTherapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 177.68M | 33.34M | 33.00M | $ 54.69M | $ -8.72M | -1.24 | -30.20 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Protalix BioTherapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PLX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.79 | 5.36 | 4.71 | 5.16 | 644,177 | 0.54 | 11.27% |
| 1 Month | 4.75 | 5.48 | 4.395 | 4.97 | 491,469 | 0.58 | 12.21% |
| 3 Months | 3.99 | 7.02 | 3.82 | 5.06 | 924,549 | 1.34 | 33.58% |
| 6 Months | 3.82 | 7.02 | 3.12 | 4.86 | 496,804 | 1.51 | 39.53% |
| 1 Year | 2.55 | 7.02 | 2.45 | 4.50 | 341,125 | 2.78 | 109.02% |
| 3 Years | 0.4722 | 7.02 | 0.17 | 1.49 | 475,961 | 4.86 | 1,028.76% |
| 5 Years | 0.8701 | 7.02 | 0.17 | 1.05 | 785,565 | 4.46 | 512.57% |
Protalix BioTherapeutics Description
| Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa, for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. Its pipeline products include Alidornase Alfa, Pegunigalsidase Alfa, and Oprx-106. The company's primary sources of revenues include its sales of taliglucerase alfa in Brazil and of drug substance to Pfizer under its Amended Pfizer Agreement. |
